Market Research Logo

Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)(By Type - Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North Ameri

Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)(By Type - Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North America, Europe, APAC, Latin America, MEA; By Country - USA, Canada, UK, Germany, India, Brazil, South Africa)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global anemia drugs market on the basis of Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia), By Region (North America, Europe, APAC, Latin America, MEA); By Country (USA, Canada, UK, Germany, India, Brazil, South Africa).

Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.

Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.

Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 – 2021F, on account of rising incidences of anemia globally.North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.

According to Azoth Analytics research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa)

Scope of the Report

The report provides Segmentation and Pipeline Analysis by Anemia Type

  • Iron Deficiency Anemia
  • Chronic Kidney Disease related Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia
The report provides coverage by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)
The report provides coverage by Country
  • USA
  • Canada
  • UK
  • Germany
  • India
  • Brazil
  • South Africa
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.


1. Research Methodology
2. Executive Summary
3. Strategic Recommendations
3.1. North America and Europe to Generate High Revenue
3.2. Opportunity in Rare Anemia
3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers
4. Global Anemia Drugs Market: An Overview
4.1. Product Overview
4.2. Global Anemia Drugs Market
4.1.1. By Value (Historic 2011-15)
Table 1: Global Anemia Drugs Market, 2011-2015 (USD Billion)
4.1.2. By Value (Forecast 2016E-2021F)
Table 2: Global Anemia Drugs Market , 2016E-2021F (USD Billion)
4.3. Global Iron Deficiency Anemia Drugs Market
4.2.1. By Value (Historic 2011-15)
Table 3: Global Iron Deficiency Anemia Drugs Market, By Value, 2011-2015 (in USD Billion)
4.2.2. By Value (Forecast 2016E-2021F)
Table 4: Global Iron Deficiency Anemia Drugs Market, By Value, 2016-2021F (in USD Billion)
4.4. Global CKD Anemia Drugs Market
4.4.1. By Value (Historic 2011-15)
Table 5: Global CKD Anemia Drug Market, By Value, 2011-2015 (in USD Billion)
4.4.2. By Value (Forecast 2016E-2021F)
Table 6: Global CKD Anemia Drug Market, By Value, 2016-2021F (in USD Billion)
4.5. Global Sickle Cell Anemia Drugs Market
4.5.1. By Value (Historic 2011-15)
Table 7: Global Sickle Cell Anemia Drug Market , By Value, 2011-2015 (in USD Million)
4.5.2. By Value ( Forecast 2016E-2021F)
Table 8: Global Sickle Cell Anemia Drug Market , By Value, 2016-2021F (in USD Million)
4.6. Global Aplastic Anemia Drugs Market
4.6.1. By Value (Historic 2011-15)
Table 9: Global Aplastic Anemia Drugs Market, By Value, 2011-2015 (in USD Million)
4.6.2. By Value ( Forecast 2016E-2021F)
Table 10: Global Aplastic Anemia Drugs Market, By Value, 2016-2021F (in USD Million)
4.7. Anemia Drugs Pipeline Analysis
4.7.1. Sickle Cell Anemia
4.7.2. CKD Anemia
4.7.3. Aplastic Anemia
4.7.4. Iron Deficiency Anemia
4.7.5. Myelodysplastic syndrome Anemia
5. North America Anemia Drugs Market: An Analysis
5.1. North America Anemia Drugs Market
5.1.1. By Value (Historic 2011-15)
Table 11: North America Anemia Drugs Market , 2011-2015 (USD Billion)
5.1.2. By Value (Forecast 2016E-2021F)
Table 12: North America Anemia Drugs Market , 2016E- 2021F (USD Billion)
5.2. North America Anemia Drugs Market: Country Overview – US, Canada
Table 13: USA Anemia Drugs Market Size, By Value, 2011-2015 (in USD Billion)
Table 14: USA Anemia Drugs Market Size, By Value, 2016-2021F (in USD Billion)
Table 15: Population in USA with Health Insurance
Table 16: Canada Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 17: Canada Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
6. Europe Anemia Drugs Market: An Analysis
6.1. Europe Anemia Drugs Market
6.1.1. By Value (Historic 2011-15)
Table 18: Europe Anemia Drugs Market, 2011-2015 (USD Billion)
6.1.2. By Value (Forecast 2016E-2021F)
Table 19: Europe Anemia Drugs Market, 2016E- 2021F (USD Billion)
6.2. Europe Anemia Drugs Market: Country Overview – UK, Germany
Table 20: UK Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 21: UK Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Table 22: Germany Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 23: Germany Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
7. APAC Anemia Drugs Market: An Analysis
7.1. APAC Anemia Drugs Market
7.1.1. By Value (Historic 2011-15)
Table 24: APAC Anemia Drugs Market, 2011-2015 (USD Billion)
7.1.2. By Value (Forecast 2016E-2021F)
Table 25: APAC Anemia Drugs Market, 2016E - 2021F (USD Billion)
7.2. North America Anemia Drugs Market: Country Overview – India
Table 26: India Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 27: India Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
8. Latin America Anemia Drugs Market: An Analysis
8.1. Latin America Anemia Drugs Market
8.1.1. By Value (Historic 2011-15)
Table 28: Latin America Anemia Drugs Market, 2011-2015 (USD Million)
8.1.2. By Value (Forecast 2016E-2021F)
Table 29: Latin America Drugs Treatment Market, 2016E- 2021F (USD Million)
8.2. Latin America Anemia Drugs Market: Country Overview – Brazil
Table 30: Brazil Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 31: Brazil Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
9. MEA Anemia Drugs Market: An Analysis
9.1. MEA Anemia Drugs Market
9.1.1. By Value (Historic 2011-15)
Table 32: MEA Anemia Drugs Market , 2011-2015 (USD Million)
9.1.2. By Value (Forecast 2016E-2021F)
Table 33: MEA Anemia Drugs Market , 2016E- 2021F (USD Million)
9.2. MEA Anemia Drugs Market: Country Overview – South Africa
Table 34: South Africa Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Table 35: South Africa Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
10. Market Dynamics
10.1. Trends
10.2. Drivers
10.3. Challenges
11. M&A and Licensing Route to the Anemia Drugs Treatment Market
12. SWOT Analysis
13. Porter Five Force Model
14. Company Profiling and Drug Market Potential
Sickle Cell Anaemia
14.1. Global Blood Therapeutics (GBT)
14.1.1. Company Overview
Table A: Market Potential of GBT-440 on the Basis of Estimated Cases of Sickle cell Anemia
14.1.2. GBT-440 (Drug of Global Blood Therapeutics)
Table 36: Market Potential of GBT - 440
14.1.2.1 Market Potential
14.2. Bluebird bio
14.2.1. Company Overview
14.2.2. LentiGlobin BB305 (Drug of Bluebird bio)
Table 37: Testing of Lentiglobin
Table B: Market Potential of LentiGlobin BB305 on the Basis of Estimated Cases of Sickle cell Anemia
Table 38: Market Potential of LentiGlobin BB305
14.2.2.1 Stage of development
14.2.2.2 Overview
14.2.2.3 Clinical Data
14.2.2.4 Market Potential
14.3. GlycoMimetics
14.3.1. Company Overview
14.3.2. Rivipansel (Drug of GlycoMimetics)
14.3.2.1 Stage of development
14.3.2.2 Overview
14.3.2.3 Clinical Data
14.3.2.4 Market Opportunity
14.4. Mast Therapeutics
14.4.1. Company Overview
14.4.2. Vepoloxamer (Drug of Mast Therapeutics)
14.4.2.1 Stage of development
14.4.2.2 Overview
14.4.2.3 Clinical Data
14.4.2.4 Market Potential
CKD Anemia
14.5. GlaxoSmithKline
14.5.1. Company Overview
14.5.2. Daprodustat (Drug of GlaxoSmithKline)
14.5.2.1 Stage of development
14.5.2.2 Overview
14.5.2.3 Clinical Data
14.6. Fibrogen
14.6.1. Company Overview
14.6.2. Roxadustat (Drug of Fibrogen)
14.6.2.1 Stage of development
14.6.2.2 Overview
14.6.2.3 Clinical Data
14.7. Akebia therapeutics
14.7.1. Company Overview
14.7.2. Vadadustat (Product of Akebia therapeutics)
14.7.2.1 Stage of development
14.7.2.2 Overview
14.7.2.3 Clinical Data
14.8. Bayer AG
14.8.1. Company Overview
14.8.2. Molidustat (Drug of Bayer)
14.8.2.1 Stage of development
14.8.2.2 Overview
14.8.2.3 Clinical Data
14.9. Eli Lilly
14.9.1. Company Overview
14.9.2. BMP-6 Mab (Drug of Eli Lilly)
14.9.2.1 Stage of development
14.9.2.2 Overview
14.9.2.3 Clinical Data
14.9.3. Sotatercept (Drug of Eli Lilly)
14.9.3.1 Stage of development
14.9.3.2 Overview
14.9.3.3 Clinical Data
Aplastic Anemia
14.10. Regen biopharma
14.10.1. Hemaxellerate (Product of Regen biopharma)
14.10.1.1 Overview
14.10.1.2 Stage of development
14.10.2 BL-8040 (Drug of Bioline RX)
14.10.2.1 Overview
14.10.2.2 Stage of development
14.10.2.3 Clinical Data
Myelodysplastic syndrome
14.11. Acceleron Pharma
14.12. Celgene Corporation
14.12.1. Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.12.1.1 Overview
14.12.1.2 Stage of development
14.12.1.3 Clinical Data
14.13. Onconova Therapeutics
14.13.1 Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.13.1.1 Overview
14.13.1.2 Stage of development
14.13.1.3 Clinical Data
Iron Deficiency Anemia
14.14. Pieris Pharmaceuticals
14.14.1. PRS-080 (Drug of Pieris Pharmaceuticals)
14.14.1.1 Overview
14.14.1.2 Stage of development
14.14.1.3 Clinical Data

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report